tangrui nateglinide tablet 120mg per tablet 30tablets per carton

Description

Indication & Scope

TangRui® is a prescription oral meglitinide antidiabetic agent indicated, in combination with diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with metformin when additional blood glucose control is required.

Mechanism: Nateglinide stimulates rapid, glucose-dependent insulin secretion from pancreatic β-cells by closing ATP-sensitive potassium (KATP) channels, helping reduce postprandial blood glucose excursions.
Drug class: Meglitinide (rapid-acting insulin secretagogue).
Clinical use: Treatment of adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone, either alone or combined with metformin.

Specification

Generic Name	Nateglinide Tablets
Brand Name	TangRui®
Ingredient	Nateglinide
Dosage Form	Tablet
Package	120 mg/tablet, 30 tablets/carton
Conditions Treated	Glycemic control in adults with type 2 diabetes mellitus
Taboos	Hypersensitivity to nateglinide; type 1 diabetes mellitus; diabetic ketoacidosis
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 30°C in a dry place, protected from light.
Manufacturer	Jiangsu Deyuan Pharmaceutical Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	H20123016
Approval Date	August 5, 2021
Shelf Life	24 months

How to use ?

Recommended Dose: The usual starting dose is 60 mg or 120 mg taken three times daily before main meals. The dose should be individualized according to blood glucose response, with a maximum recommended dose of 120 mg per meal.

Time: Take 1–15 minutes before each main meal. Skip the dose if a meal is skipped.

Instructions for use: Take orally with water before meals. Use together with diet and exercise. Do not take an extra dose if a meal is missed, and do not double the next dose. Nateglinide may be used alone or in combination with metformin when additional glycemic control is needed.

Interaction: The glucose-lowering effect may be enhanced by other antidiabetic agents, insulin, salicylates, or beta-blockers, while corticosteroids, thyroid hormones, thiazide diuretics, and certain sympathomimetics may reduce its effectiveness. CYP2C9 and CYP3A4 inhibitors or inducers may alter nateglinide exposure.

Side effects: The most common adverse reactions include hypoglycemia, dizziness, upper respiratory tract infection, nausea, abdominal discomfort, diarrhea, headache, and mild elevations of liver enzymes. Allergic skin reactions may occur rarely.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support